Amaurosis fugax

Summary

Amaurosis fugax (MONDO:0043310) is a disease and 3 clinical trials. A subtype of blindness (disorder) — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	amaurosis fugax
Mondo ID	MONDO:0043310
MeSH	D020757
ICD-10-CM	G45.3
ICD-11	691084626
NCIT	C84550
SNOMED CT	88032003
UMLS	C0149793
MedGen	57702
Is cancer (heuristic)	no

Also known as: amaurosis fugax · blindness, monocular, transient · blindness, transient monocular · monocular blindness, transient · transient monocular blindness

Disease family

This is a subtype of blindness (disorder). Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › perceptual disorders › vision disorder › blindness (disorder) › amaurosis fugax

Related subtypes (3): cortical blindness, night blindness, microcephaly microphthalmos blindness

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01645306	PHASE2	COMPLETED	Revacept in Symptomatic Carotid Stenosis
NCT01445613	Not specified	COMPLETED	Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy
NCT03753893	Not specified	COMPLETED	Ocular Manifestations in Rheumatic Diseases